Browse HKDC1

Summary
SymbolHKDC1
Namehexokinase domain containing 1
Aliases FLJ37767; FLJ22761; hexokinase domain-containing protein 1; Putative hexokinase HKDC1
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00349 Hexokinase
PF03727 Hexokinase
Function

-

> Gene Ontology
 
Biological Process GO:0001678 cellular glucose homeostasis
GO:0005996 monosaccharide metabolic process
GO:0006090 pyruvate metabolic process
GO:0006091 generation of precursor metabolites and energy
GO:0006096 glycolytic process
GO:0006165 nucleoside diphosphate phosphorylation
GO:0006732 coenzyme metabolic process
GO:0006733 oxidoreduction coenzyme metabolic process
GO:0006757 ATP generation from ADP
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009126 purine nucleoside monophosphate metabolic process
GO:0009132 nucleoside diphosphate metabolic process
GO:0009135 purine nucleoside diphosphate metabolic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009144 purine nucleoside triphosphate metabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009161 ribonucleoside monophosphate metabolic process
GO:0009167 purine ribonucleoside monophosphate metabolic process
GO:0009179 purine ribonucleoside diphosphate metabolic process
GO:0009185 ribonucleoside diphosphate metabolic process
GO:0009199 ribonucleoside triphosphate metabolic process
GO:0009205 purine ribonucleoside triphosphate metabolic process
GO:0016052 carbohydrate catabolic process
GO:0019318 hexose metabolic process
GO:0019362 pyridine nucleotide metabolic process
GO:0033500 carbohydrate homeostasis
GO:0042278 purine nucleoside metabolic process
GO:0042593 glucose homeostasis
GO:0044262 cellular carbohydrate metabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0044724 single-organism carbohydrate catabolic process
GO:0046031 ADP metabolic process
GO:0046034 ATP metabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0046496 nicotinamide nucleotide metabolic process
GO:0046835 carbohydrate phosphorylation
GO:0046939 nucleotide phosphorylation
GO:0051156 glucose 6-phosphate metabolic process
GO:0051186 cofactor metabolic process
GO:0072524 pyridine-containing compound metabolic process
GO:1901657 glycosyl compound metabolic process
Molecular Function GO:0004340 glucokinase activity
GO:0004396 hexokinase activity
GO:0005536 glucose binding
GO:0008865 fructokinase activity
GO:0019158 mannokinase activity
GO:0019200 carbohydrate kinase activity
GO:0030246 carbohydrate binding
GO:0048029 monosaccharide binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04066 HIF-1 signaling pathway
hsa04910 Insulin signaling pathway
hsa04973 Carbohydrate digestion and absorption
hsa00010 Glycolysis / Gluconeogenesis
hsa00051 Fructose and mannose metabolism
hsa00052 Galactose metabolism
hsa00500 Starch and sucrose metabolism
hsa00520 Amino sugar and nucleotide sugar metabolism
hsa00524 Butirosin and neomycin biosynthesis
hsa01100 Metabolic pathways
hsa01200 Carbon metabolism
Reactome -
Summary
SymbolHKDC1
Namehexokinase domain containing 1
Aliases FLJ37767; FLJ22761; hexokinase domain-containing protein 1; Putative hexokinase HKDC1
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HKDC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolHKDC1
Namehexokinase domain containing 1
Aliases FLJ37767; FLJ22761; hexokinase domain-containing protein 1; Putative hexokinase HKDC1
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HKDC1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHKDC1
Namehexokinase domain containing 1
Aliases FLJ37767; FLJ22761; hexokinase domain-containing protein 1; Putative hexokinase HKDC1
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HKDC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1320.703
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1970.728
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0950.85
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1270.872
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4620.742
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.860.564
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0410.954
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.5680.131
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.5770.144
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3080.825
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.280.889
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6740.0399
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HKDC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277306.8-6.80.32
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275908.5-8.50.32
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHKDC1
Namehexokinase domain containing 1
Aliases FLJ37767; FLJ22761; hexokinase domain-containing protein 1; Putative hexokinase HKDC1
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HKDC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHKDC1
Namehexokinase domain containing 1
Aliases FLJ37767; FLJ22761; hexokinase domain-containing protein 1; Putative hexokinase HKDC1
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HKDC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HKDC1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHKDC1
Namehexokinase domain containing 1
Aliases FLJ37767; FLJ22761; hexokinase domain-containing protein 1; Putative hexokinase HKDC1
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HKDC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHKDC1
Namehexokinase domain containing 1
Aliases FLJ37767; FLJ22761; hexokinase domain-containing protein 1; Putative hexokinase HKDC1
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HKDC1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHKDC1
Namehexokinase domain containing 1
Aliases FLJ37767; FLJ22761; hexokinase domain-containing protein 1; Putative hexokinase HKDC1
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HKDC1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHKDC1
Namehexokinase domain containing 1
Aliases FLJ37767; FLJ22761; hexokinase domain-containing protein 1; Putative hexokinase HKDC1
Chromosomal Location10q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HKDC1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.